
Christel Vangestel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4421391/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments. Pharmaceutics, 2022, 14, 939.	4.5	4
2	Immuno-PET Molecular Imaging of RANKL in Cancer. Cancers, 2021, 13, 2166.	3.7	3
3	Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update. Cancers, 2020, 12, 1868.	3.7	33
4	Bone metastases in the era of targeted treatments: insights from molecular biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 98-111.	0.7	8
5	[99m Tc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference. Nuclear Medicine and Biology, 2018, 56, 1-9.	0.6	11
6	Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer. Molecular Imaging and Biology, 2017, 19, 109-119.	2.6	2
7	Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography. Molecular Imaging and Biology, 2017, 19, 762-771.	2.6	6
8	Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology. Molecular Imaging and Biology, 2017, 19, 560-569.	2.6	16
9	Coadministration of a Gloriosa superba extract improves the in vivo antitumoural activity of gemcitabine in a murine pancreatic tumour model. Phytomedicine, 2016, 23, 1434-1440.	5.3	11
10	Early Prediction of Tumor Response to Treatment: Preclinical Validation of ^{99m} Tc-Duramycin. Journal of Nuclear Medicine, 2016, 57, 805-811.	5.0	30